Jounce gets $261mm up front in major Celgene immuno-oncology deal; deal ends
Jounce Therapeutics Inc. and Celgene Corp. teamed up to co-develop and sell Jounce's lead immuno-oncology candidate JTX2011 and up to five additional early-stage immunotherapies.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.